Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    UroGen Pharma Ltd.

    NASDAQ: URGN · Real-Time Price · USD
    14.35
    2.32 (19.29%)
    At close: Jun 16, 2025, 3:59 PM
    14.34
    -0.07%
    Pre-market: Jun 17, 2025, 05:19 AM EDT

    UroGen Pharma Statistics

    Share Statistics

    UroGen Pharma has 46.11M shares outstanding. The number of shares has increased by 12.07% in one year.

    Shares Outstanding

    n/a
    		 46.11M

    Shares Change (YoY)

    n/a
    		 12.07%

    Shares Change (QoQ)

    n/a
    		 9.23%

    Owned by Institutions (%)

    n/a
    		 84.16%

    Shares Floating

    n/a
    		 39.62M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,336

    FTD / Avg. Volume

    n/a
    		 0.06%

    Short Selling Information

    The latest short interest is 3.92M, so 8.49% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.92M

    Short % of Shares Out

    n/a
    		 8.49%

    Short % of Float

    n/a
    		 8.67%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -3.6 and the forward PE ratio is -8.5. UroGen Pharma's PEG ratio is 0.22.

    PE Ratio

    n/a
    		 -3.6

    Forward PE

    n/a
    		 -8.5

    PS Ratio

    n/a
    		 5.05

    Forward PS

    n/a
    		 0.9

    PB Ratio

    n/a
    		 -51.87

    P/FCF Ratio

    n/a
    		 -4.7

    PEG Ratio

    n/a
    		 0.22
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for UroGen Pharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.01, with a Debt / Equity ratio of -14.02.

    Current Ratio

    n/a
    		 6.01

    Quick Ratio

    n/a
    		 5.81

    Debt / Equity

    n/a
    		 -14.02

    Debt / EBITDA

    n/a
    		 -1.12

    Debt / FCF

    n/a
    		 -1.27

    Interest Coverage

    n/a
    		 -7.73

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $386,316.24

    Profits Per Employee

    n/a
    		 $-542,196.58

    Employee Count

    n/a
    		 234

    Asset Turnover

    n/a
    		 0.32

    Inventory Turnover

    n/a
    		 0.96

    Taxes

    Income Tax

    n/a
    		 2.83M

    Effective Tax Rate

    n/a
    		 -2.28%

    Stock Price Statistics

    The stock price has increased by -21.5% in the last 52 weeks. The beta is 0.4, so UroGen Pharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.4

    52-Week Price Change

    n/a
    		 -21.5%

    50-Day Moving Average

    n/a
    		 8.75

    200-Day Moving Average

    n/a
    		 10.92

    Relative Strength Index (RSI)

    n/a
    		 77.11

    Average Volume (20 Days)

    n/a
    		 2,384,285

    Income Statement

    In the last 12 months, UroGen Pharma had revenue of 90.4M and earned -126.87M in profits. Earnings per share was -2.96.

    Revenue

    n/a
    		 90.4M

    Gross Profit

    n/a
    		 81.52M

    Operating Income

    n/a
    		 -96.78M

    Net Income

    n/a
    		 -126.87M

    EBITDA

    n/a
    		 -110.33M

    EBIT

    n/a
    		 -111.52M

    Earnings Per Share (EPS)

    n/a
    		 -2.96
    Full Income Statement

    Balance Sheet

    The company has 171.99M in cash and 123.39M in debt, giving a net cash position of 48.6M.

    Cash & Cash Equivalents

    n/a
    		 171.99M

    Total Debt

    n/a
    		 123.39M

    Net Cash

    n/a
    		 48.6M

    Retained Earnings

    n/a
    		 -806.22M

    Total Assets

    n/a
    		 247.62M

    Working Capital

    n/a
    		 195.18M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -96.77M and capital expenditures -295K, giving a free cash flow of -97.06M.

    Operating Cash Flow

    n/a
    		 -96.77M

    Capital Expenditures

    n/a
    		 -295K

    Free Cash Flow

    n/a
    		 -97.06M

    FCF Per Share

    n/a
    		 -2.26
    Full Cash Flow Statement

    Margins

    Gross margin is 90.18%, with operating and profit margins of -107.06% and -140.35%.

    Gross Margin

    n/a
    		 90.18%

    Operating Margin

    n/a
    		 -107.06%

    Pretax Margin

    n/a
    		 -137.22%

    Profit Margin

    n/a
    		 -140.35%

    EBITDA Margin

    n/a
    		 -122.05%

    EBIT Margin

    n/a
    		 -107.06%

    FCF Margin

    n/a
    		 -107.37%

    Dividends & Yields

    URGN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for URGN is $25, which is 74.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $25

    Price Target Difference

    n/a
    		 74.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.48

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist